UroGen Pharma Ltd (NASDAQ: URGN) started the day on Thursday, with a price decrease of -2.94% at $18.8, before settling in for the price of $19.37 at the close. Taking a more long-term approach, URGN posted a 52-week range of $3.42-$21.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 10.39% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 10.39%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -3.44%. This publicly-traded company’s shares outstanding now amounts to $46.20 million, simultaneously with a float of $39.55 million. The organization now has a market capitalization sitting at $869.77 million. At the time of writing, stock’s 50-day Moving Average stood at $17.31, while the 200-day Moving Average is $12.08.
UroGen Pharma Ltd (URGN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. UroGen Pharma Ltd’s current insider ownership accounts for 14.51%, in contrast to 92.29% institutional ownership. According to the most recent insider trade that took place on Aug 11 ’25, this organization’s Chief Medical Officer sold 10,000 shares at the rate of 17.69, making the entire transaction reach 176,900 in total value, affecting insider ownership by 148,229. Preceding that transaction, on Jul 28 ’25, Company’s General Counsel sold 7,522 for 19.14, making the whole transaction’s value amount to 143,971. This particular insider is now the holder of 41,492 in total.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Let’s observe the current performance indicators for UroGen Pharma Ltd (URGN). It’s Quick Ratio in the last reported quarter now stands at 3.99. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.23.
In the same vein, URGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.32, a figure that is expected to reach -0.64 in the next quarter, and analysts are predicting that it will be -1.03 at the market close of one year from today.
Technical Analysis of UroGen Pharma Ltd (URGN)
If we take a close look at the recent performances of UroGen Pharma Ltd (NASDAQ: URGN), its last 5-days Average volume was 1.24 million that shows plunge from its year to date volume of 1.53 million. During the previous 9 days, stock’s Stochastic %D was recorded 49.08% While, its Average True Range was 44.71%.
Raw Stochastic average of UroGen Pharma Ltd (URGN) in the period of the previous 100 days is set at 87.41%, which indicates a major rise in contrast to 28.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.91 that was lower than 1.03 volatility it exhibited in the past 100-days period.
